Syneos Health India Private Limited

At Novonesis, we believe that solutions rooted in biology are the key to tackling the biggest challenges our world faces. Our team of more than 10,000 colleagues across 30+ industries works together to transform how the world produces, consumes, and lives. We operate with a culture of collaboration and innovation, drawing on over a century of combined expertise from our heritage companies. Our people thrive in an environment where sustainability is not just a goal but a fundamental part of how we work - where every contribution helps build healthier lives and a healthier planet. We are inherently sustainable because we draw from nature, and we embrace the diverse perspectives that drive our innovation forward. Our inclusive culture fosters belonging and respect, ensuring that everyone can bring their authentic selves to work while making meaningful impact. Whether developing enzymes, functional proteins, or microorganisms, we operate with the conviction that biology holds the answers to humanity's most pressing challenges. We empower our teams with real ownership and cross-functional collaboration, optimizing for impact rather than hierarchy.

Monte Rosa Therapeutics is a clinical-stage biotechnology company focused on developing highly selective molecular glue degrader (MGD) medicines for patients living with serious diseases. The company’s work centers on degrading proteins - 'Degrading Proteins, Making Medicines' - and advancing precision approaches that target undruggable or inadequately drugged proteins with unprecedented specificity. On its website, the team is described as combining expertise in molecular glue degrader (MGD) chemistry, artificial intelligence (AI), structural biology, and proteomics. Monte Rosa’s QuEEN
9 (Quantitative and Engineered Elimination of Neosubstrates) discovery engine is described as using AI-guided chemistry alongside diverse chemical libraries, structural biology, and proteomics to identify degradable protein targets and rationally design MGDs. The company positions this platform as enabling access to a wide-ranging, differentiated target space across multiple therapeutic areas, and references advancing multiple MGD programs through its pipeline. The company is headquartered in Boston, Massachusetts, and also lists a Basel, Switzerland location on its site.

At Agenus, we're driven by a singular, unwavering mission: to end the suffering of cancer patients. For over 30 years, our team of scientists, researchers, and professionals has been united by this purpose, working collaboratively across the US and Europe to discover, develop, and manufacture breakthrough immuno-oncology therapies. Our research and innovation engine has built a comprehensive pipeline of novel immunotherapies that empower the body to recognize and eliminate disease. We believe that the key to transforming cancer treatment lies in harnessing the full power of the immune system - activating it to do what it was meant to do. Our culture is defined by scientific excellence, relentless innovation, and an unwavering focus on patients. We thrive on tackling the toughest challenges in oncology, particularly in areas where current therapies fall short - cold tumors and late-stage cancers that have resisted traditional treatments. The people who thrive here are those who share our passion for making a meaningful difference, who embrace collaboration across disciplines, and who are motivated by the potential to deliver curative therapies to patients who need them most. Every day, we're pushing the boundaries of what's possible in immunotherapy, united by our vision of a future where more patients live longer, fuller lives.

The purpose of Idorsia is to discover, develop, and commercialize innovative medicines to help more patients. We have more ideas, we see more opportunities, and we want to transform the horizon of therapeutic options. Headquartered in Switzerland – a biotech-hub of Europe – Idorsia is a high-potential biopharmaceutical company, specialized in the discovery, development and commercialization of innovative small molecules. Our team is dedicated to bringing innovative medicines from bench to bedside, with operations spanning multiple locations across North America, Europe, and Asia. We conduct research, clinical development, and commercial operations out of these global locations. Idorsia's corporate responsibility efforts encompass employee development and diversity, governance and ethics, as well as the organization's economic, environmental, and social performance.

Thermo Fisher Scientific is the world leader in serving science, enabling customers to make the world healthier, cleaner and safer. The company delivers an unrivaled combination of innovative technologies, purchasing convenience and pharmaceutical services through its industry-leading brands. With a global team of more than 120,000 colleagues, Thermo Fisher serves customers across pharmaceutical and biotechnology companies, hospitals and clinical diagnostic labs, universities, research institutions, government agencies and industrial organizations. The company's portfolio includes leading brands such as Thermo Scientific, Applied Biosystems, Invitrogen, Fisher Scientific, Unity Lab Services, Patheon and PPD. Thermo Fisher provides comprehensive solutions through its analytical instruments, laboratory equipment, software, services, consumables and reagents. The company's integrated offerings span from research and discovery to diagnosis and cure, accelerating innovation and driving advancements in life sciences, healthcare and industrial markets.

At FHI 360, we believe in putting opportunity within reach through collaboration and locally driven solutions. Our team of more than 2,200 experts works across over 50 countries, partnering with communities to develop data-driven approaches to global challenges. We listen first, then act - working alongside local organizations to expand economic opportunity, improve health outcomes, and respond to humanitarian crises with culturally attuned strategies. Our culture is built on six core values: innovation to meet evolving needs, mutual respect for diversity, passion driven by personal commitment, accountability through measurable results, commitment to excellence with high ethical standards, and teamwork across disciplines. Since 1971, we have evolved from conducting family planning research at the University of North Carolina to a global nonprofit that addresses interconnected challenges in health, education, nutrition, economic development, environment, and civil society. We advocate for access and opportunity for all people, enabling them to create their own paths forward through enduring networks and integrated solutions.